Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00606645 | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | PHASE1 | COMPLETED | 23 | — | — | Dec 1, 2007 | Apr 1, 2010 | Apr 21, 2014 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | XmAb2513 |
| Name | Type | Description |
|---|---|---|
| XmAb2513 | BIOLOGICAL | Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts. |
Inclusion Criteria: * Diagnosed with HL or ALCL. * Patients must have received two or more prior therapeutic regimens, one of which should include hematopoietic cell transplant, either autologous or allogeneic transplant. * If a hematopoietic cell transplant was refused, or the patient was not elig...